8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported April 1, 2009

Humana Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of Incorporation)

1-5975	61-0647538
(Commission File Number)	(IRS Employer Identification No.)

500 West Main Street, Louisville, KY	40202
(Address of Principal Executive Offices)	(Zip Code)

502-580-1000

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

On April 7, 2009, Humana Inc. (the “Company”) announced that Jonathan T. Lord, M.D., Senior Vice President – Chief Innovation Officer, will leave the Company to become Chief Executive Officer of Navigenics, Inc. A copy of the press release related to the announcement is attached hereto as Exhibit 99 and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits:

Exhibit No.	Description
99	Press Release, dated April 7, 2009

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

HUMANA INC.
BY:	/s/ Steven E. McCulley
	Steven E. McCulley
	Vice President and Controller (Principal Accounting Officer)

Dated: April 7, 2009

INDEX TO EXHIBITS

Exhibit No.	Description
99	Press Release, dated April 7, 2009

EX-99

Exhibit 99

news release Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40201-1438 http://www.humana.com

FOR MORE INFORMATION, CONTACT:
Regina Nethery
Humana Investor Relations
502-580-3644
RNethery@humana.com
Thomas Noland
Humana Corporate Communications
502-580-3674
TNoland@humana.com

Jonathan Lord to Become CEO of Navigenics

LOUISVILLE, Ky. — April 7, 2009 — Humana Inc. (NYSE: HUM) announced today that Jonathan Lord, M.D., Humana’s senior vice president and chief innovation officer, has been named chief executive officer of Navigenics, Inc., a Foster City, Calif.-based personal genomics company that uses DNA testing and analysis to determine an individual’s genetic predisposition for various health conditions with the goal of improving health outcomes in individuals across the population.

Dr. Lord, who joined Humana in 2000 as the company’s first chief innovation officer, will leave Humana and assume his new position May 1.

“As a physician-researcher and a hands-on health futurist, Jack Lord has become a global leader in health care innovation, promotion and prevention,” said Mike McCallister, president and chief executive officer of Humana. “For the past nine years, his work as the founding head of Humana’s Innovation Center has powerfully transformed the company and the entire health benefits industry.”

Among Dr. Lord’s accomplishments at Humana were the design and implementation of innovative products and services that enable consumers to choose, finance and use their health benefits with confidence and success, including SmartSuite health plans and the ground-breaking SmartSummary and SmartSummary Rx comprehensive benefits statements. In recent years he

- MORE -

1

news release Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY40201-1438 http://www.humana.com

and his team developed a number of industry-leading, consumer-focused health and wellness initiatives including HealthMiles, the Freewheelin bike-sharing program and Humana Games4Health.

Before coming to Humana, Dr. Lord was president of Health Dialog in Boston, where he helped pioneer e-enabled health care. He has also served as chief operating officer of the American Hospital Association in Washington, D.C., and is currently a member of the advisory committee to the director of the Centers for Disease Control in Atlanta.

McCallister said a successor to Dr. Lord would likely be named in the near future.

About Humana

Humana Inc., headquartered in Louisville, Kentucky, is one of the nation’s largest publicly traded health, and supplemental benefits companies, with approximately 10.6 million commercial medical and Medicare Advantage members. Humana is a full-service benefits solutions company, offering a wide array of health and supplementary benefit plans for employer groups, government programs and individuals.

Over its 48-year history, Humana has consistently seized opportunities to meet changing customer needs. Today, the company is a leader in consumer engagement, providing guidance that leads to lower costs and a better health plan experience throughout its diversified customer portfolio.

More information regarding Humana is available to investors via the Investor Relations page of the company’s web site at http://www.humana.com, including copies of:

• Annual reports to stockholders

• Securities and Exchange Commission filings

• Most recent investor conference presentations

• Quarterly earnings news releases

- MORE -

2

news release Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY40201-1438 http://www.humana.com

• Replays of most recent earnings release conference calls

• Calendar of events (includes upcoming earnings conference call dates and times, as well as planned interaction with research analysts and institutional investors)

• Corporate Governance Information

3